News & Updates
Excerpt from the Article: COVID-19 vaccines have quickly come to the rescue. Scientists created a vaccine to prevent the new virus using foundational research and technology developed at Penn. Today, as we race to vaccinate more people in more places against COVID-19, the biology behind these vaccines is poised to change the world again: With…Read More
Excerpt from the Press Release: REDWOOD CITY, Calif., April 21, 2021 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today announced dosing of the first patient in a multicenter Phase 1/1b clinical trial evaluating RMC-5552, the company’s investigational…Read More
Excerpt from the Press Release: NEWTOWN, Pa., April 22, 2021 (GLOBE NEWSWIRE) — Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, announced today that the first patient has been dosed in an investigator-initiated Phase 2 study to assess the efficacy and safety of rigosertib…Read More
Excerpt from the Press Release: MALVERN, Pa., April 21, 2021 (GLOBE NEWSWIRE) — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that its co-development partner, Bharat Biotech, shared positive results of the second interim analysis…Read More
Excerpt from the Press Release: LA JOLLA, Calif.–(BUSINESS WIRE)–Apr. 22, 2021– DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the launch of DermTech PLAplusTM, its next generation test for the enhanced early detection of melanoma. PLAplusdelivers objective and actionable information to guide clinical management decisions…Read More
Excerpt from the Press Release: NEEDHAM, Mass.–(BUSINESS WIRE)–Candel Therapeutics, Inc., a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced it has completed enrollment for its Phase 1 clinical trial in patients with newly diagnosed high-grade glioma to evaluate the safety and efficacy of CAN-2409 in combination with immune checkpoint inhibitor Opdivo® (nivolumab) and…Read More
Excerpt from Press Release: REDWOOD CITY, Calif., April 23, 2021 (GLOBE NEWSWIRE) — Coherus BioSciences, Inc. (Nasdaq: CHRS) has received notice from immuno-oncology partner Junshi Biosciences that the Independent Data Monitoring Committee of the JUPITER-06 clinical trial has determined that toripalimab, an anti-PD-1 monoclonal antibody, in combination with paclitaxel/cisplatin as first-line treatment for patients with advanced…Read More
On April 21st, we hosted our virtual networking meeting focused on the critical benefits of engaging a Statistician early in your clinical development program. Heather and Christopher along with their guest John Amrhein of McDougall Scientific facilitated a wonderful presentation and discussion around the many different and crucial benefits of engaging a Statistician early to…Read More
Excerpt from the Article: MRI has grown in popularity as a tool to image the brain for various diseases or damage, leading to a heavy volume of scans for radiologists to interpret. Using an artificial intelligence (AI)-based system could help automate those interpretations to quickly identify the patients who need the most emergent care. “MRI…Read More
Excerpt from the Press Release: PHILADELPHIA, April 15, 2021 /PRNewswire/ — Researchers at Children’s Hospital of Philadelphia (CHOP) have identified a key target that may be responsible for treatment failure in about 30% of patients with hemophilia A. The target, known as B cell activating factor (BAFF), appears to promote antibodies against and inhibitors of the missing blood clotting…Read More
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?